Morepen Bags Rs 825 Crore Global Deal; Expands Into High-Growth CDMO Segment

Morepen Laboratories Limited has reached a major milestone by securing a multi-year CDMO mandate valued at approximately Rs 825 crore (USD 91 million) from a leading global pharmaceutical major. This agreement represents one of the most significant single contracts in the company’s history, with supplies expected to commence within the next 4–5 months. Execution is scheduled to run through the first quarter of the following financial year, contingent upon standard operational and regulatory approvals. The deal underscores Morepen's strategic expansion into the high-growth CDMO segment as it continues to scale its global manufacturing footprint.

Leveraging over four decades of API expertise, Morepen is positioning itself as a key partner for international innovators seeking reliable, long-term supply frameworks. The company’s growth is supported by a robust regulatory track record, featuring approvals from the USFDA, WHO-GMP and EU authorities. As global pharma companies consolidate their supplier networks, Morepen’s vertically integrated capabilities and commitment to capacity enhancement allow it to meet the increasing demand for compliant and scalable manufacturing platforms. This engagement further validates the company's ability to handle complex scale-ups in highly regulated global markets.

About the Company

Morepen Laboratories Ltd. is a vertically integrated, innovation-led pharmaceutical and healthcare company delivering high-quality APIs, branded generics, medical devices and consumer wellness products to over 90 countries worldwide. With a high installed API capacity, a 14 million-strong glucometer user base and a rapidly expanding digital footprint, Morepen stands at the forefront of India's health-tech evolution.

Backed by decades of trust, regulatory approvals from USFDA, WHO and EU bodies and a passion for innovation, Morepen is committed to making quality healthcare accessible, affordable and future-ready. The company has a market cap of over Rs 2,400 crore and the stock is up by 36.30 per cent from its 52-week low of Rs 33.47 per share. 

Disclaimer: The article is for informational purposes only and not investment advice.